Actinium Pharmaceuticals Profit Margin

Actinium Pharmaceuticals (ATNM) currently reports a profit margin of 32.23% as of June 2026. That is above the Healthcare sector average of 13.76%. Use the charts on this page to explore Actinium Pharmaceuticals's profit margin history and peer comparisons.

Actinium Pharmaceuticals's profit margin of 32.23% is higher than the Healthcare sector average of 13.76%. That is roughly 134.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Actinium Pharmaceuticals's current 32.23% should be judged against Healthcare norms (sector average: 13.76%) and against ATNM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 32.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.76%. From there, open related valuation or income-statement pages for Actinium Pharmaceuticals, and consider following ATNM for alerts when major investors trade the stock.

Actinium Pharmaceuticals is classified in the Healthcare sector. On profit margin, it currently shows 32.23% versus a sector average near 13.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATNM with unrelated industries.